Brevoord Judith C D, Joosten Koen F M, Arts Willem F M, van Rooij Roos W, de Hoog Matthijs
Department of Pediatrics, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
J Child Neurol. 2005 Jun;20(6):476-81. doi: 10.1177/08830738050200060201.
The efficacy of a combination of midazolam and phenytoin in treating generalized convulsive status epilepticus in children was studied retrospectively. The patient group comprised all patients admitted for generalized convulsive status epilepticus to the pediatric intensive care unit over 7 years. Patients treated according to the protocol were included (N = 122). These patients were treated with the following regimen; each subsequent step was taken if clinical evidence of epileptic activity persisted: midazolam 0.5 mg/kg rectally or 0.1 mg/kg intravenously. After 10 minutes: midazolam 0.1 mg/kg intravenously. After 10 minutes: phenytoin 20 mg/kg intravenously in 20 minutes. After phenytoin load: midazolam 0.2 mg/kg intravenously followed by midazolam 0.1 mg/kg/hour continuously, increased by 0.1 mg/kg/hour every 10 minutes to maximum 1 mg/kg/hour. Phenobarbital 20 mg/kg intravenously or pentobarbital 2 to 5 mg/kg intravenous load, 1 to 2 mg/kg/hour continuously intravenously. Patients who received initial rectal diazepam were included. Patients were categorized according to the cause of generalized convulsive status epilepticus. These categories were then related to the level of antiepileptic therapy needed. Patients' ages ranged from 0.5 to 197.4 months. The cause of generalized convulsive status epilepticus was idiopathic or febrile convulsions in two thirds of cases. Most (89%) patients were managed on midazolam and phenytoin. Generalized convulsive status epilepticus was terminated with midazolam alone in 58 patients, with the addition of phenytoin in 19 patients and with continuous midazolam in 32 patients. Thirteen patients needed additional barbiturates. The relationship between the level of antiepileptic therapy and etiology was not significant. Fifty-two patients needed artificial ventilation. Seven patients died; no deaths were directly attributable to generalized convulsive status epilepticus itself. With the use of the proposed protocol, combining midazolam and phenytoin, 89% of the cases of generalized convulsive status epilepticus could be successfully managed.
回顾性研究了咪达唑仑和苯妥英联合治疗儿童全身性惊厥性癫痫持续状态的疗效。患者组包括7年来因全身性惊厥性癫痫持续状态入住儿科重症监护病房的所有患者。纳入按照方案治疗的患者(N = 122)。这些患者接受以下治疗方案;若癫痫活动的临床证据持续存在,则采取后续每一步治疗:咪达唑仑0.5 mg/kg直肠给药或0.1 mg/kg静脉给药。10分钟后:咪达唑仑0.1 mg/kg静脉给药。10分钟后:苯妥英20 mg/kg在20分钟内静脉给药。苯妥英负荷给药后:咪达唑仑0.2 mg/kg静脉给药,随后咪达唑仑0.1 mg/kg/小时持续静脉给药,每10分钟增加0.1 mg/kg/小时,最大至1 mg/kg/小时。苯巴比妥20 mg/kg静脉给药或戊巴比妥2至5 mg/kg静脉负荷给药,1至2 mg/kg/小时持续静脉给药。纳入最初接受直肠地西泮治疗的患者。患者根据全身性惊厥性癫痫持续状态的病因进行分类。然后将这些类别与所需的抗癫痫治疗水平相关联。患者年龄范围为0.5至197.4个月。三分之二的全身性惊厥性癫痫持续状态病例病因是特发性或热性惊厥。大多数(89%)患者接受咪达唑仑和苯妥英治疗。58例患者仅用咪达唑仑终止全身性惊厥性癫痫持续状态,19例患者加用苯妥英,32例患者持续使用咪达唑仑。13例患者需要额外使用巴比妥类药物。抗癫痫治疗水平与病因之间的关系不显著。52例患者需要人工通气。7例患者死亡;无死亡直接归因于全身性惊厥性癫痫持续状态本身。使用所提议的联合咪达唑仑和苯妥英的方案,89%的全身性惊厥性癫痫持续状态病例能够成功治疗。